Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department plans to widen bariatric patient access to (a) Wegovy, (b) Mounjaro and (c) other weight management drugs.

Obesity medicines can be effective for some patients living with obesity when prescribed alongside diet, physical activity, and behavioural support. Exactly what is most appropriate for an individual is down to health care professionals to advise, in discussion with patients, and considering relevant clinical guidance.

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources, and for providing guidance for the health and care system on best practice.

The NICE has recommended orlistat, liraglutide (Saxenda), and semaglutide (Wegovy) as clinically and cost-effective drugs for weight management in adults in the NHS in England. NICE guidance includes eligibility criteria and, for some products like Saxenda and Wegovy, a restriction that these treatments should be used within specialist weight management services. The NICE is in the process of finalising its guidance on tirzepatide, also known as Mounjaro, and recently consulted on its draft recommendations.

Integrated care boards are responsible for arranging the provision of health services within their area in line with local priorities, considering population need and relevant guidance. This includes the commissioning of NHS specialist weight management services.